How to Make a Regenerative Medicine
Regenerative medicine has long carried the aura of the mythic, from Prometheus’s eternally renewing liver to Wolverine’s capacity for accelerated repair.
15th July 2026Restore Harmony. Extend Health.
Developing first-in-class oral regenerative medicines.
Istesso is rethinking how we manage chronic disease. Rather than trying to stop or slow disease progression, we focus on restoring the body’s natural capacity to repair itself and return to health.
Our pioneering approach centers on mitochondrial Complex I modulators, or MCMs, a new class of oral small molecule drugs that repair and regenerate tissue across multiple organs and disease settings. Our lead clinical program, leramistat, is in Phase 2 trials, and we are expanding MCMs to other chronic age-related diseases with a pipeline of assets, each holding blockbuster potential.
"The ability to repair and regenerate damaged tissue offers us the enormous and game-changing potential to rethink how we treat and manage chronic diseases and age-related decline. It’s hard to imagine anything more rewarding and exciting than that"
Latest news
Sarcopenia Market and Landscape
Sarcopenia represents one of the largest remaining untapped pharmaceutical markets. Defined by the progressive loss of skeletal muscle mass, strength, and physical performance with aging or chronic disease, it affects tens of millions of adults worldwide and drives enormous healthcare costs through falls, frailty, loss of independence, and increased mortality. This document outlines the current market and landscape of Sarcopenia, including the opportunities, challenges and strategic implications.
26th June 2026
Istesso initiates Phase 2 clinical trial of leramistat in sarcopenia
London, UK, 16th June 2026. Istesso, the leader in oral...
16th June 2026